Regeneron Pharmaceuticals, Inc. v. Samsung Bioepis, CO., LTD., > Summary

Court Case Number 1:23-cv-00094

Filing Date Nov 21, 2023

Court West Virginia Northern District Court

Status Unknown

JudgesThomas S. Kleeh, Thomas S. Kleeh

Related Patents

Doc No	Title	Issue date
11788102	CHO integration sites and uses thereof	Oct 17, 2023
11769597	Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF	Sep 26, 2023
11753459	Anti-VEGF protein compositions and methods for producing the same	Sep 12, 2023
11732024	VEGF antagonist formulations suitable for intravitreal administration	Aug 22, 2023
11707506	Use of a VEGF antagonist to treat angiogenic eye disorders	Jul 25, 2023
11559564	Use of a VEGF antagonist to treat angiogenic eye disorders	Jan 24, 2023
11555176	Cell culture medium for eukaryotic cells	Jan 17, 2023
11548932	Anti-VEGF protein compositions and methods for producing the same	Jan 10, 2023
11542317	Anti-VEGF protein compositions and methods for producing the same	Jan 3, 2023
11535663	Methods for producing aflibercept in chemically defined media having reduced aflibercept variants	Dec 27, 2022
11485770	Anti-VEGF protein compositions and methods for producing the same	Nov 1, 2022
11472861	Methods for producing aflibercept in chemically defined media having reduced aflibercept variants	Oct 18, 2022
11332771	Serum-free cell culture medium	May 17, 2022
11312936	Taurine supplemented cell culture medium and methods of use	Apr 26, 2022
11306135	Anti-VEGF protein compositions and methods for producing the same	Apr 19, 2022
11299532	Anti-VEGF protein compositions and methods for producing the same	Apr 12, 2022
11253572	Use of a VEGF antagonist to treat angiogenic eye disorders	Feb 22, 2022
11174283	Anti-VEGF protein compositions and methods for producing the same	Nov 16, 2021
11104715	Methods for producing aflibercept in chemically defined media having reduced aflibercept variants	Aug 31, 2021
11084865	VEGF antagonist formulations suitable for intravitreal administration	Aug 10, 2021
11066458	VEGF antagonist formulations suitable for intravitreal administration	Jul 20, 2021
11053280	Anti-VEGF protein compositions and methods for producing the same	Jul 6, 2021
10927342	Taurine supplemented cell culture medium and methods of use	Feb 23, 2021
10918754	Sterilisation method	Feb 16, 2021
10905786	Sterilisation method	Feb 2, 2021
10888601	Use of a VEGF antagonist to treat angiogenic eye disorders	Jan 12, 2021
10828345	Use of a VEGF antagonist to treat angiogenic eye disorders	Nov 10, 2020
10669594	Compositions and methods for detecting a biological contaminant	Jun 2, 2020
10464992	VEGF antagonist formulations suitable for intravitreal administration	Nov 5, 2019
10415055	Enhanced expression and stability regions	Sep 17, 2019
10130681	Use of a VEGF antagonist to treat angiogenic eye disorders	Nov 20, 2018
09816110	CHO integration sites and uses thereof	Nov 14, 2017
09562238	Enhanced expression and stability regions	Feb 7, 2017
09315281	System and methods for use in dispensing biopharmaceutical materials	Apr 19, 2016
09254338	Use of a VEGF antagonist to treat angiogenic eye disorders	Feb 9, 2016
09222106	Enhanced expression and stability regions	Dec 29, 2015
07070959	Modified chimeric polypeptides with improved pharmacokinetic properties	Jul 4, 2006

Lawsuits

Regeneron Pharmaceuticals, Inc. v. Samsung Bioepis, CO., LTD., > Summary

Plaintiff

Defendant

Plaintiff Attorneys

Defendant Attorneys

Counter Defendant

Counter Claimant

Related Patents